Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Are Biosimilars The Next Big Opportunity In India?

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - The Indian biosimilars market is a multi-billion dollar opportunity for Indian and multinational companies to tap into, albeit via different routes, according to a white paper released this month by global consultancy Frost & Sullivan

You may also be interested in...



Biocon Chairman Kiran Mazumdar-Shaw On Hopes For An Oral Diabetes Drug, And Risks And Rewards Of Innovation: An Interview with PharmAsia News

Biocon Chairman And Managing Director Kiran Mazumdar-Shaw shares her business development strategy and newest pipeline developments with PharmAsia News in an exclusive interview.

With Filgrastim, Rituximab And Darebepoetin Alfa Under Its Belt, India's Dr. Reddy's Set To Launch Fourth Biosimilar - Pegfilgrastim

MUMBAI - Keeping with its track record of launching a range of biosimilars before its peers, India's Dr. Reddy's Laboratories Ltd. is set to launch its indigenously developed pegylated filgrastim - a version of Amgen Inc.'s blockbuster Neulasta used to boost white blood cells in patients undergoing chemotherapy. Neulasta had global sales of around $3.6 billion last year, said an expert in the biotechnology industry

With No Big Push For R&D Or Infrastructure, Indian Budget Belies Pharma Industry Hopes

MUMBAI - The keenly watched "Union Budget" of the Indian government made no direct references or moves that could benefit the Indian pharmaceutical industry - leaving most senior level executives disappointed and hoping for progressive steps in the future

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC078020

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel